GoAI
Get started
Imunon, Inc. logo

Imunon, Inc.

IMNN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.64

+$0.06 · +3.80%

Aug 21, 4:00 PM ET

IMNN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

44

Fair Value

Momentum

21

Weakening

Sentiment

58

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Stacy R. Lindborg
Listed since
Mar 1, 1999
Employees
20

Market position

Day range

Current $1.64

52-week range

Current $1.64

Open
$1.61
Previous close
$1.58
Volume
58.86K
0.58× average
Average volume
101.1K
Average daily volume
Market cap
6.89M USD
Beta
1.97
Market reference 1
50-day average
$1.7486
-6.21% below average
200-day average
$2.8589
-42.64% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
315.63K USD
P/E (TTM)
-0.36×
P/B (TTM)
2.05×
P/S (TTM)
0×
EV / EBITDA
-0.02×
Earnings yield
-179.20%
Free cash flow yield
-175.27%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-205.25%
Return on assets
-117.96%
Return on invested capital
-181.53%

Financial health

Debt / equity
1.87×
Current ratio
2.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends828%-2084%-4996%-7908%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -4201.44%Operating margin, FY2022: -4984.31%Net margin, FY2021: -4153.85%Net margin, FY2022: -7179.65%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -4201.44%. Operating margin FY2022 -4984.31%. Net margin FY2021 -4153.85%. Net margin FY2022 -7179.65%.

Income trends

Revenue

500K USD0.00%

Operating income

−14.65M USD+23.42%

Net income

−14.5M USD+22.15%
Income trends across reported periods4.14M USD−10.42M USD−24.98M USD−39.54M USDRevenue, FY2021: 500K USDRevenue, FY2022: 500K USDOperating income, FY2021: −21.01M USDOperating income, FY2022: −24.92M USDOperating income, FY2023: −21.03M USDOperating income, FY2024: −19.13M USDOperating income, FY2025: −14.65M USDNet income, FY2021: −20.77M USDNet income, FY2022: −35.9M USDNet income, FY2023: −19.51M USDNet income, FY2024: −18.62M USDNet income, FY2025: −14.5M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 500K USD. Revenue FY2022 500K USD. Operating income FY2021 −21.01M USD. Operating income FY2022 −24.92M USD. Operating income FY2023 −21.03M USD. Operating income FY2024 −19.13M USD. Operating income FY2025 −14.65M USD. Net income FY2021 −20.77M USD. Net income FY2022 −35.9M USD. Net income FY2023 −19.51M USD. Net income FY2024 −18.62M USD. Net income FY2025 −14.5M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———500K USD500K USD
Gross profit———500K USD500K USD
Research and development7.78M USD11.64M USD11.29M USD11.73M USD10.62M USD
Selling, general, and administrative6.87M USD7.49M USD9.74M USD13.69M USD10.89M USD
Operating expenses14.65M USD19.13M USD21.03M USD25.42M USD21.51M USD
Interest income155.67K USD450.22K USD725.82K USD502.58K USD18.15K USD
Interest expense——197.08K USD5.03M USD569.88K USD
Depreciation and amortization698.9K USD718.12K USD720.01K USD731.63K USD702.92K USD
Operating income−14.65M USD−19.13M USD−21.03M USD−24.92M USD−21.01M USD
Net income−14.5M USD−18.62M USD−19.51M USD−35.9M USD−20.77M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
-82.63%
11 comparable reports
Latest EPS result
-0.54
Estimate -0.87 · Beat by 37.75%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.46-1.98-3.5-5.02Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -3.26, estimate -4.69, surprise +30.47%, Beat. Q2 2025, reported May 12, 2025: actual -3.65, estimate -4.56, surprise +19.96%, Beat. Q3 2025, reported Aug 5, 2025: actual -1.87, estimate -3.09, surprise +39.48%, Beat. Q4 2025, reported Nov 13, 2025: actual -1.16, estimate -1.2, surprise +3.22%, Beat. Q1 2026, reported Mar 31, 2026: actual -1.29, estimate -1.43, surprise +9.79%, Beat. Q2 2026, reported May 12, 2026: actual -0.84, estimate -1.22, surprise +30.86%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.54, estimate -0.868, surprise +37.75%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.61, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates135K128.33K121.67K115KQ1 '24EstimateQ2 '24EstimateQ3 '24EstimateQ4 '24EstimateQ1 '25Estimate
Q1 2024, reported Mar 28, 2024: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q2 2024, reported May 13, 2024: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q3 2024, reported Aug 14, 2024: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 7, 2024: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q1 2025, reported Feb 27, 2025: actual —, estimate 125K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.00

509.76% upside
Past 12 months12-month forecastHigh $10.00Average $10.00Low $10.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

IMNN news

seekingalpha.com

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2 Strong enrollment…

Read source
globenewswire.com

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism

Read source
globenewswire.com

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs.…

Read source
globenewswire.com

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial

Read source
benzinga.com

Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients

Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial.

Read source

Corporate actions

Corporate action history

Stock split

Effective Jul 25, 2025

1:15

Stock split

Effective Mar 1, 2022

1:15

Stock split

Effective May 30, 2017

1:14

Stock split

Effective Oct 29, 2013

111:500

Stock split

Effective Feb 28, 2006

1:15

IMNN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IMNN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
74.68K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research IMNN

research.disclaimer